Completed PHASE3 INTERVENTIONAL 2-arm NCT02708914

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis

Sponsor: UBI Pharma Inc.

Conditions Renal Anemia

Interventions Eprex UB-851

Updated 8 times since 2017 Last updated: Nov 29, 2023 Started: Mar 31, 2016 Primary completion: Oct 31, 2021 Completion: Oct 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Renal Anemia, this trial is completed. The trial is conducted by UBI Pharma Inc. and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2024 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2021 — Jan 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Feb 2017 — Apr 2018 [monthly]

Not Yet Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UBI Pharma Inc.

Data source: UBI Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.